Histogenics Corp (NASDAQ:HSGX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, AnalystRatings.NET reports. According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the